NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Genmab A/S GMAB
6 fiscal years on record · DKK · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
DKK 3.7B
▲ 19.2% vs FY2024
EPS · FY25
DKK 15.37
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
25.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
DKK 3.7B
Revenue, FY2025 · full 6-year series below
Revenue
Net income
26 cents of every revenue dollar became profit this year.
Per share
DKK 15.37
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin28.6%
Net margin25.9%
Return on assets3.3%
Returned to shareholders
DKK 430.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksDKK 430.0M
Share of profit44.7%
Consecutive raises—
DKK 430.0M in buybacks — 45% of the year's profit went back to shareholders.
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+1.7%
Change, 10 years—
The share count grew 2% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
DKK 12.9B
total assets, end of FY2025
Total assetsDKK 12.9B
CashDKK 1.7B
Gross debtDKK 5.3B
Net debtDKK 3.6B
Current ratio2.02×
History
6 fiscal years
Every figure from documents filed with the SEC · DKK
Metric
2025
2024
2023
2019
2018
2017
Revenue DKK B
3.7
3.1
2.4
5.4
3.0
2.4
Operating income DKK B
1.1
1.0
0.8
2.6
1.4
1.3
EBITDA DKK B
·
·
·
2.7
1.4
1.4
Income tax DKK B
0.2
0.2
0.2
0.7
0.1
−0.0
Net income DKK B
1.0
7.8
4.4
2.2
1.5
1.1
EPS, diluted DKK
15.37
121.36
66.02
34.03
23.73
17.77
Dividend / sh DKK
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
Shares out B
0.06
0.07
0.07
0.07
0.06
0.06
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
14 of 16
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 2 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed